CollPlant Biotechnologies/$CLGN
1D1W1MYTD1Y5YMAX
Capital at risk
About CollPlant Biotechnologies
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
- Ticker
- $CLGN
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 39
- Headquarters
- Rehovot, Israel
- Website
- collplant.com
CLGN Metrics
BasicAdvanced
$8.6M
-
-$10.28
0.74
-
Price and volume
Market cap
$8.6M
Beta
0.74
52-week high
$4.78
52-week low
$2.99
Financial strength
Current ratio
2.268
Quick ratio
1.841
Long term debt to equity
0.38
Total debt to equity
0.542
Profitability
EBITDA (TTM)
-12.072
Gross margin (TTM)
-147.56%
Net profit margin (TTM)
-3,376.35%
Operating margin (TTM)
-3,329.05%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-61.34%
Return on equity (TTM)
-151.99%
Valuation
Price to revenue (TTM)
14.977
Price to book
1.35
Price to tangible book (TTM)
1.36
Price to free cash flow (TTM)
-0.514
Free cash flow yield (TTM)
-194.41%
Free cash flow per share (TTM)
-8.865
Growth
Revenue change (TTM)
-84.26%
Earnings per share change (TTM)
-15.08%
3-year revenue growth (CAGR)
-16.41%
3-year earnings per share growth (CAGR)
-11.92%
10-year earnings per share growth (CAGR)
-12.96%
CLGN Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.